Sangamo Biosciences News

RICHMOND, Calif., May 21, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics for HIV/AIDS, monogenic diseases and stem cell applications, were described in twelve presentations given by Sangamo scientists and collaborators at ... (more)

Sangamo BioSciences Presentation at Bank of America Merrill Lynch 2012 Health Care Conference May 16, 2012 5:20 PM ET My name's Rachel McMinn.

RICHMOND, Calif., May 7, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at the following conferences: -- The 11th Annual JMP Securities ... (more)

First quarter 2012 revenues were comprised of revenues from the Company's new collaboration and license agreement with Shire AG to develop ZFP TherapeuticsA for hemophilia and other monogenic diseases, existing collaboration agreements with Dow AgroSciences and Sigma-Aldrich Corporation, enabling technology agreements and research grants.

Good afternoon and welcome to the Sangamo BioSciences teleconference to discuss first quarter 2012 financial results.